Edition:
United Kingdom

People: TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

0.70USD
24 Jun 2019
Change (% chg)

$0.03 (+4.46%)
Prev Close
$0.67
Open
$0.66
Day's High
$0.72
Day's Low
$0.65
Volume
18,440
Avg. Vol
64,824
52-wk High
$2.80
52-wk Low
$0.50

Theuer, Charles 

Dr. Charles P. Theuer, M.D., Ph.D. is President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director of the Company. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016. In addition, since March 2018, Dr. Theuer has served on the board of directors of Oncternal Therapeutics, Inc., a private venture-backed cancer therapeutics company. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Our board of directors believes Dr. Theuer’s expertise and experience in the biotechnology industry, his medical training and his experience with our company provide him with the qualifications and skills to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 532,400
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 878,185
Fiscal Year Total, USD 1,410,580

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --